Conditions: Solid Tumors
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 39
Healthy volunteers: no

Brief summary:
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.

Detailed description:

Arms:
arm 1: lurbinectedin (PM01183) 4 mg vials of powder for concentrate for solution for infusion

Interventions: intervention 1: lurbinectedin (PM01183)
Intervention descriptions: intervention 1: None

Protocol document: